This company has been marked as potentially delisted and may not be actively trading. Ocean Biomedical (OCEA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesOptions ChainShort InterestTrendsBuy This Stock OCEA vs. ANVS, ENLV, ALLR, CMMB, EDSA, SLGL, EQ, LPCN, CING, and UBXShould you be buying Ocean Biomedical stock or one of its competitors? The main competitors of Ocean Biomedical include Annovis Bio (ANVS), Enlivex Therapeutics (ENLV), Allarity Therapeutics (ALLR), Chemomab Therapeutics (CMMB), Edesa Biotech (EDSA), Sol-Gel Technologies (SLGL), Equillium (EQ), Lipocine (LPCN), Cingulate (CING), and Unity Biotechnology (UBX). These companies are all part of the "pharmaceutical preparations" industry. Ocean Biomedical vs. Annovis Bio Enlivex Therapeutics Allarity Therapeutics Chemomab Therapeutics Edesa Biotech Sol-Gel Technologies Equillium Lipocine Cingulate Unity Biotechnology Ocean Biomedical (NASDAQ:OCEA) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Do institutionals & insiders have more ownership in OCEA or ANVS? 24.6% of Ocean Biomedical shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 73.5% of Ocean Biomedical shares are held by company insiders. Comparatively, 32.3% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer OCEA or ANVS? In the previous week, Ocean Biomedical had 1 more articles in the media than Annovis Bio. MarketBeat recorded 2 mentions for Ocean Biomedical and 1 mentions for Annovis Bio. Ocean Biomedical's average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocean Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is OCEA or ANVS more profitable? Company Net Margins Return on Equity Return on Assets Ocean BiomedicalN/A N/A -931.55% Annovis Bio N/A N/A -311.00% Do analysts rate OCEA or ANVS? Annovis Bio has a consensus target price of $37.00, indicating a potential upside of 2,234.38%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts plainly believe Annovis Bio is more favorable than Ocean Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocean Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility and risk, OCEA or ANVS? Ocean Biomedical has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Does the MarketBeat Community prefer OCEA or ANVS? Annovis Bio received 26 more outperform votes than Ocean Biomedical when rated by MarketBeat users. However, 100.00% of users gave Ocean Biomedical an outperform vote while only 93.75% of users gave Annovis Bio an outperform vote. CompanyUnderperformOutperformOcean BiomedicalOutperform Votes4100.00% Underperform VotesNo VotesAnnovis BioOutperform Votes3093.75% Underperform Votes26.25% Which has stronger valuation and earnings, OCEA or ANVS? Annovis Bio is trading at a lower price-to-earnings ratio than Ocean Biomedical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcean BiomedicalN/AN/A-$114.47M-$0.94-0.01Annovis BioN/AN/A-$56.20M-$2.56-0.62 SummaryAnnovis Bio beats Ocean Biomedical on 8 of the 14 factors compared between the two stocks. Get Ocean Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for OCEA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCEA vs. The Competition Export to ExcelMetricOcean BiomedicalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$296,000.00$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.30%P/E Ratio-0.017.1422.1418.40Price / SalesN/A238.89389.70101.29Price / CashN/A65.6738.2034.62Price / Book0.006.266.664.18Net Income-$114.47M$142.48M$3.21B$247.71M Ocean Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCEAOcean Biomedical0.1959 of 5 stars$0.01-13.3%N/A-99.2%$296,000.00N/A-0.01N/ANews CoverageGap DownANVSAnnovis Bio1.3287 of 5 stars$1.36+11.5%$37.00+2,620.6%-88.3%$19.36MN/A-0.303High Trading VolumeENLVEnlivex Therapeutics3.104 of 5 stars$0.88+2.3%$10.00+1,036.4%-32.1%$18.84MN/A-0.9070ALLRAllarity Therapeutics0.4221 of 5 stars$1.03+9.6%N/A-97.4%$17.53MN/A0.0010News CoveragePositive NewsGap UpCMMBChemomab Therapeutics3.3686 of 5 stars$1.16+3.6%$9.00+675.9%+98.8%$16.66MN/A-1.1620EDSAEdesa Biotech3.116 of 5 stars$2.38+5.3%$21.00+782.4%-46.6%$16.64MN/A-1.2720News CoverageSLGLSol-Gel Technologies2.7431 of 5 stars$0.59+6.4%$5.00+754.7%-12.1%$16.30M$11.71M-1.7250Positive NewsHigh Trading VolumeEQEquillium2.9493 of 5 stars$0.46-3.7%$3.00+559.1%-75.8%$16.26M$41.10M-3.2540News CoveragePositive NewsLPCNLipocine2.5018 of 5 stars$3.01+0.3%$10.00+232.2%-29.4%$16.10M$11.20M-3.9610Analyst ForecastGap UpCINGCingulate2.144 of 5 stars$4.07-4.0%$30.67+653.5%+396.9%$16.04MN/A-0.2820Negative NewsGap UpUBXUnity Biotechnology4.0396 of 5 stars$0.94-3.1%$5.33+467.6%-34.0%$15.85M$240,000.00-0.7260Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies ANVS Alternatives ENLV Alternatives ALLR Alternatives CMMB Alternatives EDSA Alternatives SLGL Alternatives EQ Alternatives LPCN Alternatives CING Alternatives UBX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCEA) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocean Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocean Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCEA Stock Free OCEA Stock Alerts